Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 7Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 3Hodgkin Disease 3Breast Neoplasms 3Lymphoma 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Sezary Syndrome 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasm Metastasis 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunoblastic Lymphadenopathy 1

Interventions

Temozolomide 26Radiotherapy 10Bevacizumab 10Carboplatin 6Irinotecan 5pembrolizumab 4Radiation 4Nivolumab 4IL13-PE38 4temsirolimus 3Surgical Procedures, Operative 3Magnetic Resonance Spectroscopy 3Immunotherapy, Adoptive 3Erlotinib Hydrochloride 3Aminolevulinic Acid 3trametinib 2olaparib 2lutetium Lu 177 dotatate 2fludarabine 2dabrafenib 2cemiplimab 2abemaciclib 2Vorinostat 2Transurethral Resection of Bladder 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Imatinib Mesylate 2Flucytosine 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Glioma × Panobinostat × Clear all
NCT00859222 2017-03-14

LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

Dana-Farber Cancer Institute

Phase 1/2 Completed
51 enrolled 18 charts
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡